We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RHI:NYSERobert Half Inc. Analysis

Data as of 2026-04-28 - not real-time

$26.15

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Robert Half is trading at $26.15, just above its 20‑day SMA ($26.02) and 50‑day SMA ($24.87) but well below the 200‑day SMA ($30.06), indicating a short‑term bounce in a longer‑term downtrend. The MACD line sits marginally above its signal (bullish) while the RSI is neutral at 50.7, and volume is increasing, yet 30‑day volatility is high at 62% and beta hovers around 1, suggesting price swings remain pronounced. Fundamental data show a 3.8% YoY revenue decline to $5.33 B, thin profit margins (gross 37.2%, operating 2.8%, net 2.4%) and a zero‑reported operating cash flow, while the dividend yield looks attractive at 9.0% but the payout ratio exceeds 170%, flagging sustainability concerns. Valuation appears compelling: the trailing P/E of 19.7 is well below the industry average of 31.1, forward P/E contracts to 12.7, and the price‑to‑sales ratio is only 0.5, implying the stock trades at a discount to peers. Analysts rate the stock as a “hold” with a median target of $27 and a mean target of $29.9, translating to a 14% upside, and William Blair recently upgraded RHI to Outperform. The company projects Q3 EPS growth of 8‑12% and aims to lift Protiviti’s adjusted segment margins to 7‑9%, which could re‑ignite earnings momentum. However, the recent earnings beat ($0.14 EPS vs. consensus) was offset by a share price decline of 5.1% after the results, reflecting market sensitivity to the revenue dip. The Fear & Greed Index sits at “Extreme Greed” (89.25), indicating bullish sentiment that may be pricing in optimistic growth expectations. Overall, the stock sits at a valuation sweet spot but carries notable execution and dividend sustainability risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Earnings beat but revenue decline
  • Technical neutrality with modest bullish MACD
  • Unsustainable dividend payout

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward P/E of 12.7 vs industry 31.1
  • Analyst upgrade to Outperform
  • Projected Q3 EPS growth of 8‑12%

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Cyclical staffing exposure
  • Dividend sustainability concerns
  • Valuation discount but modest long‑term growth outlook

Key Metrics & Analysis

Financial Health

Revenue Growth-3.80%
Profit Margin2.43%
P/E Ratio19.7
Debt/Equity19.25
P/B Ratio2.0
Industry P/E31.1

Technical Analysis

TrendNeutral
RSI50.7
Support$23.01
Resistance$30.24
MA 20$26.02
MA 50$24.87
MA 200$30.06
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25

Valuation

Target Price$29.89
Upside/Downside14.30%
GradeUndervalued
TypeBlend
Dividend Yield9.02%

Risk Assessment

Beta1.04
Volatility62.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.